1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Chengdu Kanghong Pharmaceutical Group Co., Ltd

Chengdu Kanghong Pharmaceutical Group Co., Ltd

002773.SZ
Chengdu Kanghong Pharmaceutical Group Co., LtdCN flagShenzhen Stock Exchange
22.28
CNY
-1.41
- -
20.53BMarket Cap
Chengdu Kanghong Pharmaceutical Group Co., Ltd
002773.SZ
(Shenzhen Stock Exchange)

Recent

price

22.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.24
1.36
1.71
1.89
2.15
2.52
2.91
3.19
3.36
3.73
3.79
3.94
3.7
4.32
4.86
4.97
4.96
Revenue per Share
0.17
0.22
0.26
0.4
0.35
0.48
0.57
0.74
0.8
0.82
-0.31
0.46
0.98
1.14
1.3
1.26
1.32
Basic EPS, GAAP
0.01
0.02
0.2
0.33
0.26
0.44
0.77
0.52
-0.12
-0.17
-0.39
-0.08
0.62
1.18
1.37
1.34
-0.17
Free Cash Flow per Basic Share
0.04
0.19
0.05
0.05
0.07
0.07
0.1
0.12
0.22
0.22
0.28
0.1
0.1
0.15
0.38
0.6
- -
Dividend per Share
0.77
0.83
0.99
1.32
1.62
1.96
2.54
3.12
3.68
4.48
3.93
3.98
4.84
5.78
6.7
7.32
6.79
Book Value per Share
0.81
1.08
1.21
1.55
1.84
2.82
3.07
3.63
3.77
3.79
5.97
6.28
7.12
8.08
9
9.6
9.08
Tangible Book Value per Share
641
748
780
780
780
824
873
872
869
873
870
915
915
916
916
923
930
Basic Weighted Avg Shares
796
1,017
1,331
1,477
1,675
2,074
2,540
2,786
2,917
3,257
3,295
3,605
3,389
3,957
4,453
4,585
4,612
Sales/Revenue/Turnover
17.74
20.23
19.39
20.19
18.61
19.85
20.4
27.32
24.9
23.61
-17.42
14.08
27.63
29.46
28.63
28.26
28.85
Operating Margin (%)
27
31
49
58
67
65
63
65
74
93
118
149
158
223
230
238
- -
Depreciation Expense
109
165
203
316
273
394
497
644
695
718
-270
421
897
1,045
1,191
1,163
1,229
Net Income, GAAP
20.98
18.36
17.97
14.31
18.11
13.01
11.91
15.58
13.07
14.01
- -
- -
15.96
16.43
12.98
15.53
12.64
Effective Tax Rate (%)
13.63
16.23
15.23
21.38
16.33
18.98
19.56
23.12
23.82
22.05
-8.19
11.68
26.46
26.4
26.75
25.36
26.64
Profit Margin (%)
62
242
406
707
958
1,860
2,284
2,884
2,793
2,278
2,981
3,031
3,535
4,651
5,634
6,483
5,986
Working Capital
- -
2
2
- -
- -
- -
- -
396
342
278
1
4
3
1
3
2
2
LT Debt
625
936
1,106
1,389
1,612
2,525
2,905
3,543
4,084
4,621
5,756
6,105
6,907
7,812
8,647
9,275
8,849
Total Equity
17.67
19.26
19.19
19.73
16.65
16.98
16.44
18.38
14.82
13.92
- -
- -
12.03
13.18
13.42
12.14
13.59
Return on Invested Capital (%)
22.17
26.28
26.68
33.35
23.17
26.74
25.6
23.18
19.66
18.58
- -
- -
22.89
21.71
21.05
18.34
20.82
Return on Capital (%)
23.53
29.54
29.04
35.07
23.91
27.4
25.93
26.07
23.46
20.2
-7.36
11.92
22.22
21.48
20.82
18.03
20.54
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2
1
2
LT Borrowings
- -
- -
- -
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
920
920
921
Market Capitalization
17,856
23,210
26,950

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
6,289
6,698
6,632
Cash, Cash Equivalents & STI
5,690
6,076
5,999
Accounts Receivable, Net
177
197
202
Inventories
387
364
373
Total Current Liabilities
655
586
646
Payables & Accruals
- -
- -
- -
ST Debt
2
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.02%
10.05%
7.26%
Free Cash Flow
-73.41%
-166.09%
-0.9%
Net Income, GAAP
-18.54%
-22.99%
-2.37%
Sales/Revenue/Turnover
8.53%
7.13%
2.98%
Total Cash Common Dividend
- -
- -
58.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,093
1,201
1,117
1,041
4,453
2025
1,199
1,255
961
- -
4,585
2026
1,046
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
- -
- -
- -
1.3
2025
0.43
- -
- -
- -
1.26
2026
0.33
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.38
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
- -
Similar Companies
Mega Lifesciences Public Company Limited (MEGA.BK)
Little Green Pharma Ltd (LGP.AX)
CMG Pharmaceutical Co., Ltd. (058820.KQ)
Jiangsu Kanion Pharmaceutical Co.,Ltd. (600557.SS)
Suven Life Sciences Limited (SUVEN.NS)
Lincoln Pharmaceuticals Limited (LINCOLN.NS)
Business
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the discovery, creation, manufacturing, and distribution of biological products, traditional Chinese medicines, chemical pharmaceuticals, and medical devices. The company provides a range of treatments primarily targeting ophthalmic, central nervous system, digestive system, and endocrine system conditions. Its portfolio includes key drugs such as Conbercept for various macular degenerations and other eye diseases, alongside a pipeline actively developing innovative gene therapies and oncology solutions for global markets. Founded in 1996, the company is headquartered in Chengdu, China.